April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Corneal Endothelial Cell Density in Patients With Neovascular Age-related Macular Degeneration Treated With Ranibizumab in the EXCITE Study
Author Affiliations & Notes
  • R. H. Guymer
    Centre for Eye Research Australia, University of Melbourne, East Melbourne, Australia
  • R. O. Schlingemann
    Academisch Medisch Centrum Universiteit, Amsterdam, The Netherlands
  • R. Axer-Siegel
    Department of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel
  • B. Eldem
    Department of Ophthalmology, Hacettepe University, Medical School, Ankara, Turkey
  • on behalf of the EXCITE study group
    Centre for Eye Research Australia, University of Melbourne, East Melbourne, Australia
  • Footnotes
    Commercial Relationships  R.H. Guymer, Novartis, C; R.O. Schlingemann, Novartis, C; Novartis, R; R. Axer-Siegel, None; B. Eldem, None.
  • Footnotes
    Support  Novartis Pharma
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2367. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. H. Guymer, R. O. Schlingemann, R. Axer-Siegel, B. Eldem, on behalf of the EXCITE study group; Corneal Endothelial Cell Density in Patients With Neovascular Age-related Macular Degeneration Treated With Ranibizumab in the EXCITE Study. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2367.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To explore the effect of ranibizumab treatment over 12 months on corneal endothelial cell (CEC) density in patients with neovascular age-related macular degeneration (AMD).

Methods: : In the double-masked, active-controlled, multi-center EXCITE study AMD patients with predominantly classic, minimally classic, or occult lesions without classic component were randomized into 3 treatment arms: (1) 3 initial monthly injections (loading phase) followed by quarterly injections of 0.3 mg ranibizumab (n=120), (2) loading phase and quarterly injections of 0.5 mg ranibizumab (n=118), and (3) monthly 0.3 mg ranibizumab injections (n=115). The change of CEC density from baseline to Month 12 was determined by non-contact specular microscopy. The 12-months CEC density data were adjusted for age-related yearly cell loss of 0.6%. In the analysis only patients who had ≥2000 CEC/mm2 at baseline were included.

Results: : Baseline mean values for all 3 treatment groups were within the range of 2414-2561 CEC/mm2. Compared to baseline, the mean CEC density at Month 12 increased by 11 CEC/mm2 in the 0.5 mg quarterly group (n=19) and decreased by 15 and 55 CEC/mm2 in the 0.3 mg quarterly (n=20) and 0.3 mg monthly (n=20) treatment groups, respectively. In both 0.3 mg treatment groups, 20% of patients lost >10% CEC from baseline to Month 12 whereas 11% of patients did so in the 0.5 mg quarterly treatment group.

Conclusions: : Based on the CEC density analysis of EXCITE patients, there is no consistent signal toward an increased risk for patients to lose CEC when treated with ranibizumab (monthly and quarterly dosing) over 12 months.

Clinical Trial: : www.clinicaltrials.gov NCT00275821

Keywords: vascular endothelial growth factor • age-related macular degeneration • cornea: endothelium 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×